Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Haiying Tang
Institution:
The University of Texas at San Antonio Health Science Center
Observed institution:
The University of Texas at San Antonio Health Science Center
ORCID:
0009-0009-4364-8476
Observed ORCID:
0009-0009-4364-8476
OpenAlex ID:
A5141108824
Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
·
Clinical Cancer Research
·
3
Supplementary Figure S2 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S1 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S5 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S5 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S7 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S10 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S9 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S6 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S9 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S8 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S1 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S11 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S4 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Data from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S4 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S2 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S10 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S6 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S3 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S3 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S7 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S8 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Show more works
View as search
Works count:
23
Citation count:
3
H-index:
1
I10-index:
Year
Topic
Type